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Equine infectious anemia virus (EIAV) causes rapid development of acute disease followed by recurring episodes of fever,
thrombocytopenia, and viremia. Most infected equid eventually bring the virus under immunological control. We recently reported the
development of an equine-specific ribonuclease protection assay (RPA) to quantitate mRNA levels of 10 cytokines. Using this newly
developed RPA, we now show significant differences in cytokine induction in equine monocyte-derived macrophages (EMDM) exposed to
virulent and avirulent EIAV. Virulent EIAV17 induced significant increases in interleukin (IL)-1a, IL-1h, IL-6, IL-10, and tumor necrosis
factor (TNF)-a by 0.5–1 h postinfection (hpi). In contrast, the avirulent virus failed to induce any of the tested cytokines above that of control
levels. These data show a direct correlation between cytokine dysregulation and EIAV pathogenesis.
D 2004 Elsevier Inc. All rights reserved.
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Equine infectious anemia virus (EIAV) belongs to the
family Retroviridae, genus lentivirus. The clinical course of
EIAV infection is classically divided into acute, chronic, and
inapparent carrier phases. The acute phase occurs within 5–
30 days postinfection (dpi) and is characterized by viremia,
fever, and thrombocytopenia (Issel and Coggins, 1979;
Sellon et al., 1994). The acute symptoms vary from mild
to severe to fatal depending on the strain of EIAV and the
host immune status. Following the acute phase, the infected
animal may develop chronic EIA, which manifests as
recurring cycles of fever, severe anemia, weight loss,
thrombocytopenia, hemorrhages, and anorexia (Issel and
Coggins, 1979). About 90% of the infected horses survive0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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120-749, South Korea.the chronic phase and become clinically normal. Subsequent
clinical episodes can be elicited in inapparent carriers by
environmental stress or immunosuppressive drugs (Cheevers
and McGuire, 1985). As in all retroviral infections, infected
horses remain life-long carriers of EIAV (Issel and Coggins,
1979; Kono et al., 1976).
Tissue macrophages are the primary sites for EIAV
replication and serve as cellular reservoirs during acute and
persistent infection (Oaks et al., 1998; Sellon et al., 1992).
EIAV can infect circulating monocytes, but virus expression
is limited to differentiated tissue macrophages. Macro-
phages are the source of a myriad of cytokines, and
perturbation of cytokine expression has been shown in
other lentivirus-infected macrophages including human and
simian immunodeficiency viruses (HIV and SIV, respec-
tively), caprine arthritis encephalitis virus (CAEV), and
maedi-visna virus (MVV) (Adeyemo et al., 1997; Borne-
mann et al., 1997; Ebrahimi et al., 2000; Horvath et al.,
1991; Lechner et al., 1997; Legastelois et al., 1998; Sopper
et al., 1996; Zink et al., 2001). Cytokines produced by
infected macrophages have been shown to impact the
outcome of lentiviral infections. For example, interleukin-05) 295–306
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the neurological impairment associated with late-stage HIV
and SIV infection by facilitating infiltration of macrophages
into the CNS and stimulating production of neurotoxic
substances by activated macrophages and microglia (Oran-
dle et al., 2001; Sopper et al., 1996; Tan and Guiloff, 1998;
Xiong et al., 2000). Macrophage-secreted cytokines and
chemokines, including IL-1, IL-6, type I interferons (IFN
type 1, TNF-a, RANTES, and macrophage inflammatory
proteins-1a and 1h (MIP-1a and 1h), are known to regulate
the expression and replication of HIV in macrophages and
CD4+ T-lymphocytes (Fauci, 1996; Vicenzi et al., 1997).
Therefore, investigating the interaction of EIAV with equine
monocytes and macrophages is important to the study of
EIAV-induced disease.
In this study, viruses derived from two EIAV molecular
clones, EIAV19 and p19/wenv17, were examined for
induction of cytokines in equine monocyte-derived macro-
phages (EMDM). Virus derived from clone EIAV19 causes
an asymptomatic infection in Shetland ponies (Payne et al.,
1994). p19/wenv17 is a chimeric clone generated by
replacing the 5Vand 3Vlong terminal repeats (LTR) and the
env sequences of EIAV19 with those derived from the highly
virulent Wyoming field strain of EIAV (EIAVWyo) (Payne et
al., 1998). p19/wenv17 produces a virus named EIAV17 that
causes severe EIA in infected Shetland ponies (Payne et al.,
1998). In vitro, however, both viruses replicate to high titer
and induce cytopathic effects (CPE) in EMDM. Cytokine
profiles of EMDM infected with EIAV19 or EIAV17 were
determined to evaluate the correlation between cytokine
dysregulation and EIAV pathogenesis. We utilized a newly
developed set of antisense RNA probes to quantitate the
mRNA expression of 10 equine cytokine genes by
ribonuclease protection assay (RPA) (Lim et al., 2003).Results
Characterization of EIAV17 and EIAV19
To verify the infectivity and compare the replication of
the viral stocks, EMDMs were infected with 3000 cpm RT
activity of EIAV17 or EIAV19 or were mock infected. Virus
replication was monitored by measuring RT activity in
culture supernatants. As shown in Fig. 1A, EIAV17 and
EIAV19 replicated to the same levels in EMDM culture
indicating that both virus stocks remained infectious
following the process of purification and concentration. To
further evaluate and compare the initial infectivity of the
two virus stocks, provirus copy numbers were determined at
4 hpi of EMDM infected with equivalent RT units of
EIAV17 and EIAV19. A quantitative real-time PCR assay
using SYBR Green dye was performed as described in the
methods. Using DNA from infected cells, specific product
was detected before cycle 29 while uninfected controls and
no template reactions showed no specific product throughcycle 40. Provirus copy numbers were calculated per
nanogram of input DNA, and as shown in Fig. 1B, there
is about a 3-fold difference in the average provirus copy
numbers. A set of control reactions was performed to
determine if the virus stocks contained contaminating viral
DNA that might have contributed to the amplification
signals. Comparison of DNAse-treated to untreated virus
stocks was performed, and it was verified that the treatment
did not reduce the provirus copy numbers detected at 4 hpi
of EMDM (data not shown). Therefore, the data presented
in Figs. 1A and B suggest that equivalent RT units of input
virus represent approximately equivalent levels of infec-
tious, replication-competent virus.
The SU protein content of EIAV17 and EIAV19 stocks
containing equal cpm of RT activity was estimated by
Western blot analysis using a monoclonal antibody specific
to a conserved epitope of EIAV SU (Hussain et al., 1987). A
difference in electrophoretic mobility between the SU of the
two viruses was evident (Fig. 1C), likely due to a difference
in their glycosylation since EIAV17 SU has five more
potential N-linked glycosylation sites than EIAV19 (Payne
et al., 1998). Using Control Media (CM) as background,
densitometry scans revealed EIAV19 SU concentration is 2.2-
fold higher than the SU derived from the virulent clone
indicating elevated concentrations of EIAV17 SU are not
responsible for the differential cytokine induction. Further,
Western blots were completed using equine immune sera.
EIAV19 showed 3-fold greater capsid protein (Fig. 1D),
agreeing with the SU Western blot data.
EIAV17-stimulated expression of IL-1a, IL-1b, IL-6, and
TNF-a in EMDM
Initial experiments were performed to determine the
effects of EIAV19 and EIAV17 on equine macrophage
cytokine expression. EMDMs were cultured for 7 days
and infected with EIAV19 or EIAV17 or mock-infected with
CM. At 2, 4, 12, and 24 hpi, lysates of the infected cells
were analyzed with the multiprobe RPA for IL-1a, IL-1h,
IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-g, TGF-h1,
TNF-a, and h-actin mRNA expression.
These initial studies were performed beginning at 2 hpi.
In EMDM exposed to EIAV17, there was a readily apparent
increase of IL-1a, IL-1h, IL-6, and TNF-a mRNA levels at
2 and 4 hpi (data not shown). Whereas, EIAV19 infection
induced a slight increase of IL-1h mRNA expression at 4
hpi and did not appear to affect the expression of other
cytokines (data not shown). To confirm these initial
observations, the experiment was performed in duplicate
at 2, 4, 12, and 24 hpi using EMDM derived from four
different horses (total of eight independent measurements).
Cytokine mRNA levels were analyzed by phosphor ima-
ging, normalized to the level of h-actin mRNA, and
expressed as percentage of h-actin (relative mRNA levels)
(Fig. 2). All four horses showed elevated IL-1a, IL-1h, and
IL-6 at 2 hpi when EMDMs were treated with the virulent
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rable variation in the levels of cytokine mRNA expression
by EMDM derived from different animals (Fig. 2). Hence,
to evaluate the statistical significance of changes in cytokine
mRNA expression levels, a LME model was used in which
horse-to-horse variations and variations among duplicate
measurements were taken into account by considering them
as random effects. Adequacy of the LME models was
assessed with graphical methods, and fit of the models was
deemed appropriate.
LME modeling was applied and descriptive statistics
revealed changes of relative cytokine mRNA levels in
EMDM (Table 1). At 2 hpi, the mRNA levels of IL-1a, IL-
1h, IL-6, and TNF-a in EIAV17-infected EMDM were
statistically higher than those of CM-treated EMDM (P V
0.01). IL-6 and TNF-a mRNA expression remained
significantly elevated at 4 hpi in EIAV17-infected EMDM.By 12 hpi, the mRNA levels of IL-1a, IL-1h, IL-6, and
TNF-a in EIAV17-infected EMDM were at the same levels
as those in CM-treated EMDM. In contrast, infection of
EMDM with EIAV19 did not significantly increase the
expression of any cytokine when compared to CM treatment
(Table 1). A slight but significant (P V 0.01) decrease of IL-
1a, IL-1h, IL-6, IL-8, IL-10, and TGF-h1 mRNA levels
was observed in EMDM at 12–24 h after EIAV19 infection.
The immunological effect(s) of the reduced expression of
these cytokines following infection with the avirulent virus
remains unclear. Because the assay was halted at 24 hpi, it
remains unknown if the cytokine levels recover or continue
to drop. IFN-g, IL12 p35, and IL-12 p40 mRNAs were not
detected in EMDM exposed to CM, EIAV17, or EIAV19
(data not shown).
Kinetics of cytokine mRNA levels at 0–4 hpi
Since consistent modulation of cytokine expression
occurred during the early stages of infection (2 and 4 hpi)
and was random at the late stages (12 and 24 hpi), the
responses of these cytokine genes to EIAV infection were
investigated at early times in more detail. EMDMs were
treated with CM, EIAV19, or EIAV17, and cytokine mRNA
levels were measured at 0.5, 1, 2, and 4 hpi. In these
experiments, cytokine mRNA levels were also measured in
EMDM prior to addition of EIAV or CM to establish the
mRNA expression profile of the tested cytokines in
untreated EMDM (considered equivalent to 0 hpi).
The phosphor image of a representative RPA revealed
that the mRNA levels of IL-1a, IL-1h, IL-6, TGF-h1, and
TNF-a mRNAs in CM-treated EMDM were similar to those
in untreated EMDM (0 hpi), whereas the mRNA levels of
IL-8 and IL-10 appear to vary over time following CM
treatment (Fig. 3). The representative RPA indicated that theFig. 1. (A) Graphical representation of EIAV replication in equine
monocyte-derived macrophages (EMDM) as monitored by culture super-
natant reverse transcriptase (RT) activity. EMDM cultures were infected
with 3000 cpm of EIAV17 (E) or EIAV19 (5) based on RT activity, or were
mock infected (o). Aliquots of supernatants were removed from the
cultures at 0, 4, 8, and 12 dpi, and assayed for RT activity. The x-axis
indicates time (dpi), and the y-axis indicates RTactivity expressed as cpm/ml.
(B) Proviral copy numbers were determined by quantitative real-time
PCR. The average number of proviral copy numbers recovered per
nanogram of cellular DNA and the standard deviation are indicated. The
proviral number for EIAV17 is shown on the left and EIAV19 on the right.
These data are based on three independent assays. (C) Western blot analyses
of EIAV SU glycoproteins. Control media (CM), EIAV17, and EIAV19
stocks (both containing 60000 cpm of RT activity) were pelleted, separated
by 10% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and
probed with a monoclonal antibody specific to EIAV SU. The migration of
molecular weight markers is indicated on the left. Arrows on the right
indicate the SU migration of EIAV17 (top) and EIAV19 (bottom).
Densitometry scans indicated EIAV19 SU is at a 2.2-fold greater
concentration than EIAV SU17. (D) Western blot analyses of EIAV capsid
proteins performed as described for SU except that the primary antibody
was equine immune serum and the appropriate secondary antibody was
used.
Fig. 2. Graphical representation of relative cytokine mRNA levels in EMDM derived from four horses and infected with EIAV17 (E), EIAV19 (5), or treated
with CM (o). The x-axis shows the time (2, 4, 12, and 24 hpi) when cytokine mRNAs in EMDM were measured by RPA, and the y-axis indicates the relative
mRNA levels expressed as a percentage of h-actin mRNA. Identities of the donor horses are shown across the top.
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were increased in EIAV17-infected EMDM as early as 0.5
and 1 hpi. At 4 hpi, IL-1a, IL-1h, and IL-6 mRNAs
remained elevated in EIAV17-infected cells. There were no
apparent alterations of TGF-h1 mRNA in EIAV17-infected
EMDM. As previously noted and in contrast to EIAV17,
EIAV19 infection failed to affect cytokine expression in
EMDM. mRNAs of IFN-g, IL12 p35, and IL-12 p40 were
undetected in CM-treated EMDM and were not induced by
EIAV17 or EIAV19 infection at any of the tested times.
To ensure reproducibility, the experiment was repeated
in duplicate using EMDM derived from peripheral blood of
three different horse donors (total of six independentmeasurements). Fig. 4 shows the results of these experi-
ments with the cytokine mRNA levels compared to the h-
actin mRNA level and expressed as percentage of h-actin
(relative mRNA levels). These graphical representations
illustrate that the effects of EIAV infection and CM
treatment on cytokines were consistent, but the relative
mRNA levels were variable among EMDMs from different
animals (Fig. 4). Therefore, due to outbred animal
variation, significance of the changes in cytokine mRNA
levels was determined by LME modeling and is summar-
ized in Table 2.
Statistical analyses of results from EMDM of three horses
confirmed that there were no significant differences in IL-1a
Table 1
Comparison of cytokine mRNA levels in EIAV17- or EIAV19-infected EMDM to CM-treated EMDM at 2–24 hpi
a Ratios of cytokine mRNA levels in EIAV17- or EIAV19- infected EMDM over cytokine mRNA levels in CM-treated EMDM were derived from linear
mixed-effect models.
b Bold face and shaded indicate that the cytokine mRNA level is significantly increased above the CM level (P b 0.01).
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h1 (P = 0.9257), or TNF-a (P = 0.7205) mRNA levels
between CM-treated and untreated EMDM (data not shown).
IL-6 and IL-8 mRNA expression was significantly altered by
CM treatment (P = 0.0019 and P = 0.0008, respectively).
In EIAV17-infected EMDM, significant elevations of IL-
1a and IL-1h expression were detected as early as 0.5 hpi
and peaked at 1 hpi (Table 2). IL-1a and IL-1h mRNA
levels in EIAV17-infected EMDM were 8.7- and 6.2-fold,Fig. 3. Phosphor image showing a representative experiment of early
cytokine mRNA expression in EMDM treated with CM or infected with
EIAV19 or EIAV17 at 0.5–4 hpi. EMDMs derived from donor horse 2025
were cultured for 7 days, treated with CM (left panel) or infected with
EIAV19 (center panel) or EIAV17 (right panel), and harvested at 0.5, 1, 2,
and 4 hpi. Lysates derived from 2.35  105 EMDM were analyzed for IL-
1a, IL-1h, IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-g, TGF-h1, TNF-a,
and h-actin mRNA expression by RPA. Shown on the left are the positions
of the full-length radiolabeled probes. Indicated on the right are positions of
the individual protected fragments.respectively, higher than those in CM-treated EMDM. At 2
and 4 hpi, IL-1a and IL-1h mRNA levels in EIAV17-
infected EMDM were still significantly higher (2.8- to 5.5-
fold) than those in CM-treated EMDM. In contrast, IL-1a
and IL-1h mRNA expression was only slightly increased
(approximately 2-fold above CM) at 0.5–4 hpi in EIAV19-
infected EMDM, but the differences were not statistically
significant (Table 2). EIAV17-infected EMDM consistently
expressed significantly higher levels of IL-1a and IL-1h
mRNAs than EIAV19-infected EMDM at all of the time
points tested (data not shown).
Although an increase of IL-6 mRNA level was detected
in EIAV17-infected EMDM at 0.5 hpi, the difference was not
significant when compared to CM-treated EMDM until 1
and 2 hpi (Table 2). At 4 hpi, the IL-6 mRNA level still
appeared to be increased in EIAV17-infected EMDM when
compared to CM-treated EMDM, but again the levels were
not significantly elevated. EIAV17-induced IL-6 expression
only reached 1.8-fold above CM, even at its peak level (2
hpi). Nonetheless, it is noteworthy that the EIAV17-induced
upregulation of IL-6 mRNA was significantly higher at 1
and 2 hpi when compared to CM treatment, which itself has
an upregulating effect on IL-6 mRNA expression. In
EIAV19-infected EMDM, the IL-6 mRNA level was not
significantly different from that in the CM-treated EMDM at
any time point (Table 2).
IL-8 mRNA expression was significantly increased in
EIAV17-infected EMDM at 1 hpi (Table 2). However, since
IL-8 mRNA expression was also significantly increased in
CM-treated EMDM at 4 hpi, we were unable to determine
whether the upregulation of this gene in EIAV17-infected
EMDM was infection specific. IL-8 mRNA expression in
EIAV19-infected EMDM also fluctuated but never signifi-
cantly varied from CM levels. IL-10 mRNA was signifi-
cantly increased by EIAV17 at 0.5 hpi, peaked at 1 hpi (2-fold
increase compared to CM), and remained significantly
higher than that of the CM-treated EMDM through 2 hpi
(Table 2). At 4 hpi, EIAV17-induced IL-10 expression
decreased such that the mRNA level was no longer
significantly different from that of CM treatment. The early
Fig. 4. Graphical representation of the relative cytokine mRNA levels induced early (0.5–4 h) by EIAV17 (E) or EIAV19 (5) infection, or CM (o) treatment in
EMDM derived from three horses. The x-axis shows the time (hpi) when cytokine mRNAs in EMDM were analyzed by RPA and the y-axis indicates relative
mRNA levels (expressed as a percentage of h-actin mRNA). To quantitate the cytokine mRNA levels, radioactivity of the protected cytokine probe was
analyzed with a phosphor imager and normalized to the h-actin mRNA levels. Identities of the donor horses are indicated across the top. Each data point
represents the average of duplicate measurements (total of eight analyses per cytokine).
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absent in EIAV19-infected EMDM. TGF-h1 mRNA was
constitutively expressed in CM-treated EMDM and was not
affected by infection with either EIAV17 or EIAV19 (Table 2).
The highest levels of TNF-a mRNA were detected in
EIAV17-infected EMDM at 0.5 and 1 hpi (Fig. 4). Although
the mRNA levels decreased over time, EIAV17-infected
EMDM continued to express significantly more TNF-a
mRNA than CM-treated EMDM, while EIAV19 infection did
not affect TNF-a mRNA expression (Table 2). Takentogether, these data show that there is a clear distinction
between the virulent EIAV17 and the avirulent EIAV19 in
their effects on EMDM cytokines.Discussion
A strength of this study of cytokine induction by EIAV is
its use of EMDM, the natural host cells for EIAV, and well-
characterized, biologically distinct EIAV stocks. EIAV17 is
Table 2
Comparison of cytokine mRNA levels in EIAV17- or EIAV19-infected EMDM to CM-treated EMDM at 0.5–4 hpi
a Ratios of cytokine mRNA levels in EIAV17- or EIAV19- infected EMDM over cytokine mRNA levels in CM-treated EMDM were derived from linear
mixed-effect models.
b Bold face and shaded indicate that the cytokine mRNA level is significantly increased above the CM level (P b 0.01).
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env/rev regions of EIAV19 with those derived from the
consensus sequence of the highly virulent EIAVWyo (Payne
et al., 1998). EIAV17 and EIAV19 share common gag, pol,
tat, S2, and the first 89 amino acids of the env open reading
frame, which also includes the first coding exon of rev
(Payne et al., 1998). The most remarkable differences
between EIAV17 and EIAV19 are in the region of SU
previously identified as the primary neutralizing domain
(PND), akin to the V3 loop of HIV-1 SU (Ball et al., 1992).
There are 30 amino acid residue alterations in SU between
virulent EIAV17 and avirulent EIAV19. Experimental infec-
tion of Shetland ponies with a stock of EIAV17 causes acute
symptoms including sustained febrile episodes and profound
thrombocytopenia, and the outcome is fatal (Payne et al.,
1998). In contrast, EIAV19 replicates and causes serocon-
version in infected Shetland ponies, but fails to cause disease
(Payne et al., 1994, 1998). In experimentally infected
Shetland ponies, EIAV17 replicates to higher levels than
EIAV19; however, the two viruses replicate with near
comparable efficiencies in EMDM culture. The LTR and
Env sequences of EIAV17 have been shown to independently
contribute to the virulence phenotype (Payne et al., 2004).
We now report the differential induction of cytokines in
cultured equine macrophages infected with EIAV derived
from these distinct molecular clones. In vitro infection of
EMDM with the highly virulent EIAV17 upregulated mRNA
expression of IL-1a, IL-1h, IL-6, IL-10, and TNF-a.
Significant induction of these cytokine mRNAs was
detected at 0.5–1 hpi. The expression of these cytokines
remained elevated for up to 4 hpi and returned to control
levels thereafter. In contrast, EMDM infected with a stock of
the avirulent EIAV19 either showed no effect or decreased
cytokine expression. Hence, there was a notable difference
in the ability of the EIAV clones of distinct in vivo virulence
phenotypes to enhance cytokine expression in equine
macrophages.
We recognize there are inherent problems with the in vitro
system of monitoring EIAV-induced cytokines. First, it is
difficult to ensure an equivalent number of virions was addedto the EMDM. Second, there is the possibility that a secreted
factor, rather than the virus, induced the differential cytokine
mRNA levels. EIAV infectivity is typically monitored by RT
activity, which does not directly correspond to viral binding,
entry, or replication. In this study, two additional methods
were utilized to monitor the input virus, initial infectivity as
measured by provirus copy number and amount of SU and
capsid viral proteins. We showed a 3-fold greater initial
infectivity of EIAV17 (Fig. 1B), with a 2.2-fold reduction in
SU concentration (Fig. 1C). Given that the viral clones have
distinct SU molecules, it is possible they vary in binding
efficiency even if equivalent numbers of virions were added.
Hence, the 3-fold greater concentration of EIAV19 SU may
not reflect an increase in binding. In fact, the higher level of
initial infectivity of EIAV17 suggests its SU more efficiently
binds receptor and may account for differences seen in
cytokine induction.
The possibility of a secreted factor inducing differential
cytokine mRNA levels was considered. We were careful to
remove molecules under 100 kDa, but this does not preclude
the presence of large proteins or protein complexes
remaining in the culture media. However, it should be noted
that CM was handled identical to the media containing the
viral stocks and if a secreted product is responsible, it only
exists in the media from EIAV17-infected EMDM cultures.
The data presented in this study support and expand
previous reports of EIAV cytokine induction and patho-
genesis. For example, a positive correlation between TNF-a
gene expression and viral virulence has been reported in
ponies infected with the virulent EIAVPV and the avirulent
EIAVPR, wherein higher levels of TNF-a have been
detected in sera of EIAVPV-infected ponies than in that of
EIAVPR-infected ponies (Costa et al., 1997). TNF-a activity
is also elevated in EIAVWyo-infected Arabian foals,
EIAVWSU5-infected SCID foals (Tornquist et al., 1997),
and ponies infected with PR and PV strains of EIAV
(EIAVPR and EIAVPV, respectively) (Costa et al., 1997).
However, increased levels of TNF-a are not detected in
EIAVWSU5-infected bone marrow-derived macrophage
(BMDM) cultures, which may be due to the differences in
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1997). However, elevated plasma TNF-a levels parallel the
severity of anemia found in EIAV-infected ponies (Costa et
al., 1997), and in vitro infection of BMDM with the
virulent, cell culture-adapted EIAVWSU5 increases IL-6
activity in culture media (Swardson et al., 1997). Increased
IL-6 activity is also detected in serum of ponies exper-
imentally infected with the highly virulent EIAVWyo strain
(Sellon et al., 1998).
IL-1a, IL-1h, IL-6, and TNF-a induced by EIAV17 are
pro-inflammatory cytokines predominantly produced by
macrophages (Murtaugh et al., 1996) and are well known
for their pyrogenic activities (Dinarello, 1999). In addition
to fever, these cytokines cause anorexia and hypermetab-
olism, leading to the wasting diseases commonly seen in
HIV AIDS (Chang et al., 1998). Likewise, fever, anorexia,
and wasting are clinical manifestations of acute and chronic
EIA and characteristically coincide with viremia (Montelaro
et al., 1993), suggesting pro-inflammatory cytokines may
affect EIA pathogenesis by modulating viral replication in
vivo. This speculation is supported by the positive
association of IL-6 and TNF-a serum levels with EIAV
viremia in experimentally infected ponies (Costa et al.,
1997; Sellon et al., 1998). Possible mechanisms by which
pro-inflammatory cytokines contribute to the enhanced
replication of EIAV17 in vivo include: (i) recruitment of
uninfected monocytes to the site of viral replication through
stimulation of monocyte chemotactic factors such as that
employed by HIV-1 and SIV (Schmidtmayerova et al.,
1996; Zink et al., 2001); (ii) stimulation of adhesion
molecules that promote monocyte migration into tissue
(Sampson et al., 2002); and (iii) induction of EIAV-
activating molecules by nonmonocytic cells.
Elevated levels of serum TNF-a positively correlate with
viremia, severity of clinical signs, and vaccine-induced
disease enhancement, suggesting a pathogenic role of
TNF-a in acute EIA (Costa et al., 1997). The biological
effects of TNF-a are dose dependent, with high doses
inducing shock, tissue injury, vascular leakage, hypoxia, and
other pathological features identical to septic shock (Tracey
and Cerami, 1994), whereas prolonged exposure to low
doses of TNF-a causes cachexia. The inflammatory effects
of TNF-a are similar to those of IL-1, including migration of
leukocytes, activation of endothelial cells, and stimulation of
the hypothalamic pituitary axis (Tracey and Cerami, 1994).
IL-1 and TNF-a may exacerbate EIA anemia by
activating macrophages and neutrophils, enhancing phag-
ocytosis of complement-coated erythrocytes and may
suppress erythropoiesis by downregulating erythropoietin
production and dysregulating iron metabolism (Means,
1997, 2000), both shown to contribute to EIA anemia
(Sellon et al., 1994; Sentsui and Kono, 1987a, 1987b;
Swardson et al., 1992). IL-6, also differentially regulated by
EIAV17 and EIAV19, participates in regulating various steps
of hematopoiesis in vivo and is a potent cofactor of
hematopoietic progenitor cells in vitro (Heike and Nakahata,2002). Together with IL-10, IL-6 enhances various B cell
functions and increases total serum globulin and IgM
concentrations, which are commonly seen in EIAV-infected
horses (Russell et al., 1998; Sellon et al., 1994, 1998).
Polyclonal B cell activation by IL-6 and IL-10 may
exacerbate some of the chronic EIA pathological features
mediated by immune complexes, including hemolytic
anemia, glomerulitis, and hepatitis (Swardson et al.,
1997). Although antibody-mediated enhancement of EIAV
infection has not been directly demonstrated, vaccination of
ponies with either p26 or gp90 results in enhanced viral
replication and disease severity following challenge with
heterologous pathogenic strains of EIAV (Costa et al., 1997;
Issel et al., 1992). These data suggest a detrimental effect of
nonneutralizing antibodies.
There is accruing evidence that cytokines also contri-
bute to EIA-associated thrombocytopenia. Elevated levels
of TNF-a, TGF-h, and IFN-a are found in the plasma and
bone marrow of EIAV-infected immunocompetent and
SCID foals during and prior to the onset of thrombocy-
topenia (Tornquist et al., 1997). The prethrombocytopenic
plasma has suppressive effects on proliferation of mega-
karyocyte colonies in culture, which are at least partially
attributed to activities of TNF-a and TGF-h (Tornquist and
Crawford, 1997). Although our data failed to detect an
increase of TGF-h1 expression in EMDM infected in vitro
by either EIAV strain, other TGF-h isoforms (TGF-h2
or -h3) may be elevated in the infected horse (Toossi et al.,
1995). In addition to suppressing production of platelets,
injection of purified TNF-a induces severe thrombocyto-
penia in mice and humans possibly by stimulating
secretion of platelet agonists (Michelmann et al., 1997;
Tacchini-Cottier et al., 1998). Other studies reveal that IL-1
and IL-6 are capable of directly activating platelets in vitro
(Bar et al., 1997; Oleksowicz et al., 1994). Platelet
activation in vivo has been observed in thrombocytopenic
ponies acutely infected with EIAVWyo, such that the
accelerated removal of activated platelets potentially
contributes to the net decrease of platelets in circulation
(Russell et al., 1999).
IL-1 has a plethora of local and systemic biologic
activities, most of which are achieved through modulating
expression of the biologically active molecules within and
outside the immune system (Dinarello, 1996). For example,
IL-1 causes fever, anorexia, and lethargy, common symp-
toms of EIA, by inducing expression of prostaglandins
(Dinarello, 1996). IL-1 also induces expression of other
cytokines, including IL-6 and TNF-a, while IL-6 inhibits
production of IL-1 and TNF-a in vivo (Gadient and
Patterson, 1999).
The kinetics of IL-1 and TNF-a mRNA upregulation by
EIAV17 was remarkably similar to that observed in HIV-1
infection (Herbein et al., 1994), whereby the rapidity of the
cytokine response is due to HIV-1 SU binding to its receptor
(CD4) on the macrophage surface (Chirmule and Pahwa,
1996). To date, the involvement of receptor(s) for EIAV
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cytokine mRNAs suggests that interactions between EIAV
SU and macrophage surface molecules are sufficient to
stimulate cytokine expression. Given the marked differences
in env sequence between EIAV17 and EIAV19, it is
conceivable that the differential effects on cytokine expres-
sion are due to differential Env binding or activation of
surface molecule(s), which may be controlled by variations
in binding affinity, avidity, or specificity. This hypothesis is
supported by recent in vivo data indicating SU has a greater
impact on virulence than TM (Payne et al., 2004). EIAV17
and EIAV19 also have distinct Rev proteins and LTR
sequences, but it is highly unlikely either of these regions
impact events that occur within 0.5–4 hpi of EMDM.
To our knowledge, this is the first comprehensive study
of differential cytokine expression in equine macrophages
infected with EIAV derived from characterized molecular
clones. The most notable aspect of our findings is the
correlation of the differential in vitro effects of EIAV17 and
EIAV19 with in vivo virulence following experimental
infection. The rapid kinetics of cytokine induction post
EDMD infection strongly indicates a binding event induces
the differential cytokine responses. Additional in vivo and in
vitro studies are needed to fully realize the role(s) of
cytokines in EIAV pathogenesis, viral load, and immune
regulation.Materials and methods
Cell culture
Primary EMDM cultures were established as previously
described (Lim et al., 2003). Briefly, anti-coagulated equine
peripheral blood from EIA-negative donor horses was
centrifuged to separate the buffy coat, which was then
centrifuged through a HybriMax histopague cushion (d =
1.077 g/cm3; Sigma, St. Louis, MO) to extract equine
peripheral blood mononuclear cells (EPBMCs). EPBMCs
were washed four times, resuspended in minimum essential
medium alpha (MEMa) containing 10% adult horse serum
(GIBCO BRL, Rockville, MD), 25 mM HEPES, 100 IU/ml
penicillin, 100 Ag/ml streptomycin, 2 mM l-glutamine, 0.1
mM nonessential amino acids, and 1 mM sodium pyruvate
(complete MEMa), seeded at 3  106 cells/cm2 into tissue
culture flasks, and incubated overnight. Nonadherent cells
were removed, and the adherent monocytes were washed
twice and incubated for 7 days to allow maturation into
macrophages. Purity of the macrophage culture was esti-
mated at 95% by the a-nalphthyl acetate esterase assay
(Sigma kit no. 91-A) and by immunofluorescent microscopy
using a monoclonal antibody (I.646) specific to a cytoplas-
mic antigen of equine mononuclear phagocytes (Sellon et al.,
1998). All reagents used in EMDM culture were tested for
endotoxin by the Limulus amebocyte lysate (LAL) assay
(Associates of Cape Cod Inc., Falmouth, MA). Reagentswith an endotoxin level of 0.06 EU/ml or lower were
considered suitable for our assays. Horse sera containing less
than 0.5 EU/ml (as tested by the manufacturer) were
purchased (GIBCO BRL).
D17 cells (ATCC CCL-183), a cell line derived from
canine lung osteosarcoma, were cultured in MEM contain-
ing 10% fetal bovine serum (BioWhittaker) in 25-cm2 flasks
as previously described (Payne et al., 1998).
Generation of virus stocks
EIAV19 and EIAV17 are derived from EIAV19 and p19/
wenv17 plasmids, respectively, as reported (Payne et al.,
1998). Briefly, D17 cells were plated in 60-mm dishes at
2.5  105 cells per dish 18–24 h prior to transfection
(Calcium Phosphate Transfection System, Life Technolo-
gies). Each dish of cells was incubated with 10 Ag of
plasmid for 1.5 h at 37 8C, washed twice with phosphate-
buffered saline (PBS), and replenished with fresh media.
Virus production was monitored by reverse transcriptase
(RT) assay of culture supernatants as previously described
except that [3H]TTP was used instead of [32P]TTP
(Gregersen et al., 1988).
Viral stocks were amplified by infecting EMDM at
approximately 5  103 counts per min (cpm) of RT
activity per cell. Culture supernatants of infected EMDM
were collected when approximately 80% of the cells
displayed CPE (7–12 dpi). Growth of virus was verified
by increases in RT activity. To remove cell-secreted
molecules (especially cytokines), 100 ml of infected culture
supernatant was ultrafiltered against fresh complete MEMa
(1 l, without horse serum) using a Vivaflow 200 tangential-
flow ultrafiltration unit with a MWCO of 100 kDa
(Sartorius Corp, Edgewood, NY). The 100-kDa filter was
selected because the molecular weights of cytokines range
from 7 to 75 kDa. Ultrafiltration of 100 ml of 50 mg/ml
purified bovine serum albumin (66 kDa) solution using
these conditions removed 96% of the protein from solution
(data not shown). After ultrafiltration, RT activity of the
virus was remeasured and infectivity was verified by
growth in EMDM. Culture supernatant of mock-infected
EMDM was collected and purified under identical con-
ditions, and was termed control medium (CM). Purified
CM, EIAV19, and EIAV17 contained negligible levels of
endotoxin (0.12–0.25 EU/ml).
Quantitation of virus stocks
Three methods were used to estimate the relative
amounts of virus in each resulting stock: (1) RT activity
of the filtered stocks was determined; (2) relative infectivity
for EMDM was determined; and (3) Western blots were
done to compare levels of viral SU protein. RT assays were
performed as stated above and equivalent amounts of RT
activity were used to infect EMDM. Two measures of
infectivity for EMDM were employed: a growth curve was
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monitoring culture supernatants for RT activity at regular
intervals. In a second assay, initial infectivity of the stocks
was determined by adding equivalent amounts of RT
activity (30000 CPM) to EMDM plated in 6-well dishes.
Cells were incubated with virus for 4 h, washed in PBS, and
total cell DNA was prepared using the QIAmp Tissue Kit
(Qiagen).
Infected cell DNA was analyzed by a quantitative real-
time PCR assay to determine the provirus copy numbers
present in cells at 4 hpi. The PCR assay amplified a 99-bp
fragment of EIAV gag and the product was detected using
SYBR Green dye. Data were analyzed using an ABI 5700
machine with GeneAmp 5700 SDS Software version 1.3
(Applied Biosystems). Each 25-Al reaction contained 12.5
Al of SYBR Green PCR Master Mix, 0.3 mM dNTPs, 0.3
AM upstream primer (5V- TTCCCATGACAGCAAGGTTT-
3V) and 0.3 AM downstream primer (5V- TCCATTGTCTA-
TATGTCTGCCTAAA-3V), 5 Al of sample (containing 2–4
ng DNA), or water control. Duplicate infections were
performed for each virus stock; real-time assays were
performed in triplicate. DNA standards consisted of
pSPeiav19 plasmid DNA at 102 to 106 molecules per
reaction in triplicate. Melting curves were determined and
products were analyzed by agarose gel electrophoresis to
ensure that the amplified products were of the correct size.
To determine if viral DNA present in the infecting stocks
might influence provirus copy number, aliquots of virus
stocks, prepared as described above, were treated with
DNAse I (Amplification Grade, Invitrogen) for 1 h at RT.
DNAse-treated and untreated stocks were used to infect
cells (60000 CPM/well) and provirus copy numbers present
in cells at 4 hpi were compared.
Western blot
To determine the relative amounts of SU protein in the
two virus stocks, aliquots of EIAV19 and EIAV17 were
pelleted by centrifugation at 13000 g for 2 h. Viral pellets
were resuspended, separated by SDS-PAGE, and analyzed
by Western blotting. Primary antibody to EIAV SU was a
mouse monoclonal antibody specific to EIAV SU (EIAV
gp90(A)-86) obtained from NIH AIDS Research and
Reference Reagent Program (Hussain et al., 1987) and
used at a dilution of 1/200. Goat anti-mouse horseradish
peroxidase (HRP) conjugate was used a dilution of 1/10000
and HRP was detected using Supersignal West Femto
reagents (Pierce). An immune equine serum (dilution of
1/500) was used to detect EIAV capsid protein; the secondary
antibody was anti-horse-HRP conjugate used at a 1/5000
dilution. Relative concentrations of viral proteins were
determined by densitometry scans (MultiImage, AlphaInno-
tech Corp. with AlphaImager 2200 Documentation and
Analysis software) by directly comparing pixel numbers
from an equal area in each lane. Total numbers were
subtracted from the background control (CM).Infection of EMDM for analysis of cytokine expression
Six days postisolation, EMDMs were transferred to 6-
well plates at 2.35  105 cells/well and incubated for 24 h.
EIAV19 or EIAV17 (containing 30000 cpm of RT activity in
0.5 ml), or 0.5 ml of CM was added to each well of EMDM,
incubated for 1 h at 37 8C, and 0.5 ml of fresh complete
MEMa was added. At 0, 0.5, 1, 2, 4, 12, and 24 hpi,
EMDMs were washed with PBS, harvested by trypsiniza-
tion, and pelleted. EMDM pellets were then lysed with Lysis
Solution (Ambion, Austin, TX) at 1.6  107 cells/ml and
stored at 20 8C.
RPA
Cytokine mRNA levels were measured by RPA as
previously described (Lim et al., 2003) using the Direct
Protect Lysate RPA kit (Ambion). Eleven 32P-labeled
antisense RNA probes specific to equine IL-1a, IL-1h,
IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, IFN-g, trans-
forming growth factor-h1 (TGF-h1), TNF-a, and h-actin
mRNAs were synthesized by in vitro transcription from their
respective templates (Lim et al., 2003). Approximately 9 
104 cpm of each probe were hybridized with EMDM lysate
(derived from 2.35  105 cells) overnight and then digested
with RNase A/RNase T1 cocktail. The protected probe
fragments were isopropanol precipitated and resolved on a
20 cm (length)  16 cm (width) 5% acrylamide/8 M urea
denaturing gel. The gels were dried and exposed to a Fuji
Film Imaging Plate (Fuji Photo Co., Ltd., Kanagawa, Japan).
Abundance of the protected fragments was quantitated using
a Fuji Film Bio-imaging Analyzer BAS-1800II Phosphor
Imaging System (Fuji Photo Co., Ltd.). Cytokine mRNA
levels were calculated based on the photo-stimulated
luminescence of the cytokine bands, which are directly
proportional to the radioactivity, and were normalized to the
expression levels of h-actin mRNA (expressed as percentage
of h-actin mRNA).
Statistical analysis
Exploratory, descriptive, and inferential methods were
used to analyze the data. Exploratory data analyses included
examination of graphical displays of the cytokine data by
time for each horse. Descriptive methods included exami-
nation of summary statistics for various parameters of the
cytokine measurements (for example, ratio of mean values
at fixed time points). For inferential analyses, linear mixed-
effects (LME) models were fitted using S-PLUS both for
comparisons of changes over time among treatments (i.e.,
temporal changes) and for comparisons among treatments
for a given time (Pinheiro and Bates, 2000). For the LME
modeling, an individual animal and each replicate within an
individual animal were considered as random effects. For
comparison of temporal changes, treatment and time were
considered as fixed effects. For comparisons among treat-
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effect and data from other times were excluded from the
model.
Data were modeled using a common slope for all horses
and random intercepts. The assumption that a common slope
for all horses was appropriate for a given covariate was
examined by comparing the likelihood ratio test statistics of
a model with differing (random) slopes and intercepts for
each horse with a model with a common slope for all horses
but different intercepts for each horse. Goodness-of-fit of
the models was graphically assessed in three ways. First, the
standardized residuals were plotted against the fitted values.
These plots were examined for outliers and any evidence of
a systematic pattern, and showed that the residuals were
distributed symmetrically around zero with an approxi-
mately constant variance. Second, the normal quantile–
quantile plot of the standardized residuals did not indicate
any violations of the normality assumption. For the normal-
ity assumption of random effects, we also used a normal
quantile–quantile plot even if there were only three to four
horses. The assumptions about the random effects were not
violated. Third, the adequacy of the fitted model was better
visualized by plotting fitted curves with the observed data.
These plots showed that our model fitted well with the
observed data. For all analyses, a significance level of P V
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